Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COR388 MAD study in healthy volunteers and Alzheimer's disease
NCT03418688Phase 1Completed
- Sponsor
- IRulya Therapeutics
- Start
- Mar 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing COR388 with Placebo (2 arms). Primary endpoints: Area Under the Curve at Day 10, Maximum Plasma Concentration at Day 10 and 2 more. Started Mar 2018; status: completed.
02
Drugs
atuzaginstat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03418688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03418688.